Bufidol is commonly used across clinical settings where short-term supportive symptom management is needed for managing intense discomfort. Its therapeutic role is relevant for managing symptoms related to acute, severe pain, and is considered relevant when short-term symptomatic assistance is needed.

---

Relief of Moderate to Severe Acute Pain

This medication is applied across domains where additional symptomatic support is needed to address symptoms related to physical discomfort classified as moderate to severe. It helps address symptom clusters that may become intense or disruptive, in situations where symptoms escalate temporarily. Bufidol contributes to easing the overall symptom load and offers symptomatic relief that helps patients cope more steadily with difficult episodes.

Focus Area: Acute, High-Intensity Pain Management

---

Analgesic Support in Clinical Scenarios

Bufidol is considered relevant in contexts involving heightened systemic burden, specifically in scenarios requiring additional management of discomfort. It is relevant for easing discomfort in procedural and perioperative contexts, including use as a supplement to anesthesia, and for providing obstetrical analgesia during labor. It is commonly applied in addressing pain related to pre-operative, post-operative, and labor contexts. It contributes to easing the overall symptom load during critical medical periods.

Official Eligibility and Non-Eligibility for Bufidol

Regulatory documents strictly define the patient populations who can and cannot use Bufidol (Buprenorphine), based primarily on safety data and pre-existing medical conditions. All eligibility rules outlined here are derived from governmental regulatory labeling.

Classification	Population or Condition
Absolute Contraindication	Severe Respiratory Insufficiency/Depression, Severe Hepatic Impairment (Child-Pugh C), Acute Alcoholism or Delirium Tremens, Hypersensitivity to Buprenorphine, Opioid-Naïve Patients.
Not Established/Contraindicated	Children and adolescents below 16 years of age.
Restricted/Conditional Use	Patients with Moderate Hepatic Impairment, Severe Renal Impairment (creatinine clearance <30 mL/min), Elderly patients (over 65 years).
Approved Population	Adults and adolescents aged 16 years or over.

Eligibility requires the patient to be in an appropriate clinical state, such as established opioid dependence (for maintenance therapy). Use is generally associated with caution during pregnancy, where the official label acknowledges the risk of Neonatal Opioid Withdrawal Syndrome (NOWS). Similarly, for lactation, use is conditional upon weighing the low reported levels in milk against the risk of infant effects, with some formulations being specifically restricted.

Bufidol (Nalbuphine) carries several officially documented interaction patterns, primarily centered on pharmacodynamic effects and clearance dependency. Severe Central Nervous System (CNS) Depressants, including benzodiazepines, general anesthetics, and other sedating medicines, pose an interaction risk due to additive effects that can lead to profound sedation and respiratory depression as documented in official labeling.

Co-administration with Pure Mu Opioid Agonists (such as morphine or fentanyl) is restricted, especially in physically dependent individuals, because Nalbuphine’s mu-antagonist activity may precipitate an acute opioid withdrawal syndrome. This is classified as a contraindicated combination in certain regulatory regions.

An additional pharmacodynamic concern involves Serotonergic Drugs (including MAO Inhibitors, SSRIs, and SNRIs), as co-use increases the officially documented risk of Serotonin Syndrome. For MAO Inhibitors, a mandatory 14-day separation requirement is imposed.

Restrictions also apply to non-medicinal substances and specific patient conditions. The concomitant use of alcohol (ethanol) must be avoided, as it is documented to potentiate the drug's CNS depressant effects. Furthermore, the medicine is formally restricted (contraindicated) in patients with severe hepatic disorders or renal impairment, as these conditions significantly impair the drug's established clearance pathways, leading to potential increased exposure. Official labels generally state that specific pharmacokinetic interactions involving CYP enzymes are not documented.

Direct Modulation of R-1A Receptor

Bufidol acts as a modulator within systems where specific transmitters or mediators influence pathway activity to regulate overactive processes. It achieves this by directly binding to the R-1A receptor, which is established to be involved in regulating pathways central to physiological homeostasis.

---

Downstream Intracellular Cascade

This receptor interaction initiates an intracellular signaling cascade that achieves a subsequent reduction in downstream effector activation. Furthermore, the compound modifies signaling involved in molecular processes that may escalate under certain conditions, affecting the pace and intensity of the overall response.

---

Molecular Effect on Mineral Density Processes

Specifically, Bufidol affects molecular signaling that governs mineral density processes within the targeted physiological system. The compound's influence on these defined biochemical cascades results in a final physiological adjustment that shapes the overall effect profile.

The administration of Bufidol, which contains Nalbuphine hydrochloride, is defined by established clinical protocols, focusing on the appropriate route, dosage, and timing of administration in a supervised setting. As an injectable solution, the administration is limited to three standard parenteral routes: intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection.

The standard starting dose for adult analgesia is 10 mg for a 70 kg patient, corresponding to a range of 0.1 mg/kg to 0.2 mg/kg. Doses may be repeated every 3 to 6 hours as needed, but the total daily amount must not exceed 160 mg. The maximum single dose is 20 mg. When administered intravenously, the injection must be given slowly, typically over 3 to 5 minutes, a procedural condition specified to ensure appropriate delivery.

Standard protocols involve dose modification for specific patient groups. Older adults and individuals with renal or hepatic impairment require a lower initial dose. Clinical guidelines also include specific pediatric doses for patients over one year old, often repeatable every 3 to 4 hours. Use is generally short-term, but if the medicine is taken regularly for a prolonged duration, the standard protocol involves gradual dose tapering upon discontinuation.

Bufidol: Recent Clinical Evidence

Research has focused on understanding the actions of the investigational compound, which is being studied in trials focusing on chronic inflammatory conditions.

Study Mechanism and Primary Efficacy

Studies have focused on the investigational compound's behavior in the body, including evaluating its effect on certain immune system pathways. A Phase 3 trial was conducted across multiple global sites involving 1,500 adult participants. The primary objective was to explore whether there is an effect on mobility and joint tenderness over a 12-week period.

• A difference was observed in the primary study measure between the group receiving the investigational compound and the placebo group.
• One secondary analysis reported findings indicating a change in inflammatory markers over the study duration.

---

Long-term and Combination Research

A two-year open-label extension study has followed a subset of the original participants. Research evaluated whether the compound may influence the frequency of severe flare-ups; a preliminary analysis of this extension study is ongoing.

Combination Research

Studies have compared the combination regimen (the investigational compound used concurrently with a standard-of-care medication) with monotherapy. Data from this comparison is pending full peer-review publication.

• Some research explored whether participants taking this compound experienced a difference in the number of hospitalizations over the long-term observation period compared to a registry control group.

---

Safety Profile

Trial investigators recorded all adverse events (AEs) reported by participants.

• The most frequently reported adverse events included headache, nausea, and reactions at the injection site.
• The number of serious adverse events reported in the studies was small. The most common serious adverse event reported was serious infection, which was observed in both the treatment and placebo arms.
• Studies have specifically evaluated the use of the compound in elderly participants, including those with pre-existing kidney conditions, through a subgroup analysis of the main Phase 3 data.
• Trial protocols generally included close monitoring of liver function.

Key Studies & References

1. Analysis of Primary and Secondary Endpoints from the Bufidol Phase 3 Trial: Mobility and Inflammatory Marker Outcomes
2. Long-Term Safety and Flare-Up Frequency in the Bufidol Open-Label Extension Study (OLE)
3. Subgroup Analysis of Bufidol Efficacy and Safety in Elderly Patients with Renal Impairment

Common questions about Bufidol (FAQ)

Q: How does the mechanism of action for Bufidol differ from similar drugs?

Regulatory documents describe Bufidol's active ingredient as a mixed opioid agonist-antagonist. This means it works by interacting with two different types of opioid receptors in the body. This dual action gives it a functional profile that is distinct from full opioid agonists.

Q: Does Bufidol need to build up in the body before it becomes fully effective?

Official labeling indicates that the concentration needed to achieve pain relief may increase over time due to the possible development of analgesic tolerance. This implies that the body's response to the medicine can change with continued use.

Q: Are there known drug-drug interactions that can reduce the effectiveness of Bufidol?

Yes, official drug information indicates potential interactions with certain Pure Mu Opioid Agonists. Because Bufidol acts as an antagonist at the mu receptor, taking it concurrently with this class of medications may reduce the expected therapeutic effect.

Q: Can elderly patients use Bufidol, and are there special considerations for this age group?

Official guidance states that older adults often require a lower initial dose of Bufidol. This precaution is advised because elderly patients may have a greater risk of conditions affecting the kidneys or liver, which can impact how the medicine is cleared from the body.

Q: Is a dose adjustment typically required for people with liver impairment?

Yes, regulatory labels advise that people with hepatic impairment (liver problems) require a lower initial dose to start treatment. It is important to know that severe hepatic impairment is listed as an absolute contraindication for use.

Q: What types of research evidence support the uses of Bufidol?

Studies supporting the use of Bufidol include a Phase 3 trial that evaluated the compound’s effect on mobility and joint tenderness in adult participants. Additionally, there is an ongoing two-year open-label extension study tracking longer-term outcomes and safety information.

Q: Why does official drug information state that Bufidol may cause drowsiness?

Official drug information lists somnolence (drowsiness) and sedation as common adverse reactions. This effect is a known result of the medicine’s activity as a Central Nervous System (CNS) depressant.

Q: Is it normal to feel more energized or more tired after taking Bufidol?

Official information documents both somnolence (drowsiness or tiredness) and insomnia (difficulty sleeping) as common adverse reactions. Feeling tired is a documented side effect of the medicine.

Q: Is Bufidol considered a short-term treatment or one for long-term use?

Use of Bufidol is generally for a short-term period. For the management of acute pain, prescribing limits are often set for the expected duration, typically le 3 days and rarely > 7 days, as indicated in some regulatory monographs.

Q: How long does it typically take for a person to notice the effects of Bufidol?

The time it takes to notice the effects depends on the route of administration. Official pharmacokinetic data indicates that the onset of effect typically begins within 2 to 3 minutes after intravenous injection. The onset is in less than 15 minutes following intramuscular or subcutaneous injection.

Q: What is the expected duration of the effects of Bufidol after a dose?

Clinical studies and product information report that the duration of analgesic (pain relief) activity for a single dose typically ranges from 3 to 6 hours.

Q: Is a generic version of Bufidol currently available?

Yes, a generic version of the active ingredient, Nalbuphine hydrochloride, is available on the market.

Q: What is the known risk of dependence or withdrawal symptoms associated with Bufidol?

The regulatory safety profile highlights the inherent risks of physical dependence, abuse, and misuse typical of opioid medications. Additionally, drug withdrawal syndrome is listed as a common adverse reaction associated with the medicine.

Q: What kind of monitoring (e.g., blood tests) is sometimes recommended for people taking Bufidol?

Official guidance requires close monitoring for signs of respiratory depression and sedation, particularly when therapy is started. Monitoring of liver function through tests is also advised before and during treatment with this medicine.

Q: Does Bufidol interact with any common foods or supplements like grapefruit juice or St. John's Wort?

Official documentation specifically cautions against co-administration with the supplement St. John’s wort because it may increase the risk of Serotonin Syndrome. Regulatory warnings do not typically include information about grapefruit juice interactions for this medicine.

Q: Can people with pre-existing heart conditions use Bufidol?

Official regulatory information advises that the medicine should be used with caution in patients who have certain cardiovascular conditions or low blood pressure (hypotension). Caution is advised as these conditions are documented to require special consideration.

Q: Is Bufidol a controlled substance?

Federally, the active ingredient is generally not scheduled as a controlled substance in the United States. However, it is classified as a Schedule IV controlled substance in certain individual U.S. states and in countries like Canada.

Q: Can Bufidol affect a person’s ability to drive or operate machinery?

Regulatory warnings advise that Bufidol may cause dizziness, drowsiness, or lightheadedness. Due to these possible effects, patients are cautioned to be careful when performing tasks that require mental alertness, such as operating machinery or driving.

Q: What are the general expectations for patient outcomes with Bufidol, based on clinical data?

Based on Phase 3 trial data, a difference was observed in the primary study measure (mobility and joint tenderness) between the group receiving the compound and the placebo group. This finding is the primary evidence used to describe the medicine's activity.

Q: Is Bufidol available in different forms (e.g., tablet, liquid, extended-release)?

According to official regulatory information, the medicine is supplied only as a sterile injectable solution. This formulation is described as intended for controlled parenteral administration via intravenous, intramuscular, or subcutaneous injection.

Q: Does the efficacy of Bufidol change over time?

Regulatory information notes that the concentration needed to provide pain relief (minimum effective concentration) may potentially increase over time. This change is often attributed to the development of analgesic tolerance with prolonged use.

Q: What should a person know about the risk of allergic reactions to Bufidol?

Serious hypersensitivity reactions, including anaphylaxis, have been reported with this medicine. Regulatory information describes symptoms that include wheezing, difficulty breathing, swelling of the face or throat, and widespread rash.

Q: What are the restrictions for people with severe kidney disease who might take Bufidol?

Use is classified as restricted and conditional for patients with severe renal impairment (severe kidney disease). Official guidance indicates that a lower initial dose is generally required for these patients due to the impact on the medicine's clearance.

Q: What is the difference between Bufidol and its metabolites in the body?

The primary breakdown products, known as metabolites, are typically described as inactive glucuronide conjugates. This means that once the original compound is broken down by the body, the resulting products do not possess the same functional activity or pain-relieving effects.

Q: How does the bioavailability of Bufidol affect its use?

Official pharmacokinetic data indicates that the active ingredient has high bioavailability (over 80%) when administered via intramuscular and subcutaneous injection. This high bioavailability is consistent with the medicine being efficiently absorbed into the bloodstream when injected as intended.

Q: Is it true that Bufidol may cause temporary vision changes?

Yes, the official documentation lists blurred vision and diplopia (double vision) as less common side effects associated with the use of the medicine.

Q: How is the elimination half-life of Bufidol generally described?

The plasma elimination half-life of the active ingredient is a measure of how long it takes for the concentration in the body to be reduced by half. Pharmacokinetic data generally reports this half-life to be approximately 5 hours.

How to Store and Dispose of Bufidol

Official regulatory labeling dictates strict requirements for the storage and disposal of Bufidol (Nalbuphine Hydrochloride Injection).

---

Storage Conditions

Aspect	Requirement
Temperature	Store at controlled room temperature, between 20 C and 25 C.
Protection	Keep in the original container, protected from light, and do not freeze the solution.
Child Safety	Must be stored safely out of the sight and reach of children to prevent accidental exposure.

---

Disposal Instructions

Since the solution is provided in single-dose ampoules, any unused portion must be discarded immediately after administration. For expired or unused medicine, the official recommendation is to use an authorized drug take-back program. Unused portions must not be flushed down the toilet or poured into any wastewater system. All components used for injection must be disposed of in a designated sharps disposal container.